Key result
In patients with cardioinhibitory vasovagal syncope, implantation of a single chamber leadless pacemaker resulted in 87% of patients being free from symptoms at a mean follow-up of 404 days.
Why the study?
Pacemaker therapy for cardioinhibitory vasovagal syncope remains controversial with mixed evidence, prompting examination of single-chamber leadless pacemakers as an alternative option in this population.
Does a single chamber leadless pacemaker improve symptoms in patients with cardioinhibitory vasovagal syncope?
Observational (n=32)
Yes
Does a single chamber leadless pacemaker improve symptoms in patients with cardioinhibitory vasovagal syncope?
A single chamber leadless pacemaker successfully eliminated symptoms in 87% of patients with cardioinhibitory vasovagal syncope, suggesting it is a reasonable and safe clinical option.
No takes yet. Share an insight, caveat, or question.
Supports leadless pacemaker use in cardioinhibitory vasovagal syncope; leaves open randomized comparisons to conventional pacing.
Roberts et al. (2019) conducted an observational in cardioinhibitory vasovagal syncope (n=32). Micra Transcatheter Pacemaker System was evaluated on freedom from symptoms. In patients with cardioinhibitory vasovagal syncope, implantation of a single chamber leadless pacemaker resulted in 87% of patients being free from symptoms at a mean follow-up of 404 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: